ClinicalTrials.gg
TerminatedNCT04818580Updated Jan 30, 2023

Progressive Tension Sutures in Gender Affirming Mastectomy

An interventional study of Progressive Tension Sutures in Hematoma and Seroma, sponsored by NYU Langone Health. Terminated at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-30.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

Why this study was terminated
Departure of key personnel, difficulties with recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

50 patients seeking gender affirming mastectomy will be treated with different closure techniques in each side of their chest - one side will receive progressive tension sutures between pectoral fascia and the mastectomy flap, and the other side will not. Both sides will have drains in the mastectomy site. Rates of hematoma, seroma, and other complications will be compared between each chest side via standard statistical techniques for hypothesis testing.

02

Conditions studied

  • Hematoma
  • Seroma

Browse trials for

Keywords

  • Mastectomy
03

In context

Hematoma

109 studies on the registry are indexed under Hematoma; 19 are open to participants now.

This study's enrollment of 3 is below the median of 107 across 83 interventional studies indexed under Hematoma.

Browse Hematoma studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,430 studies on the registry; 258 are open to participants now.

Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Being consulted for gender affirming mastectomy with the senior author (AH).
  2. >18 years of age at the time of enrollment.
  3. Transgender or gender nonbinary gender identity.
  4. All co-morbidities and all indications.

Exclusion criteria

Exclusion Criteria:

  1. Age less than 18 years.
  2. \< 23.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Right-Sided Progressive Tension Sutures

    Procedure: Progressive Tension Sutures

  • Active comparator
    Left-Sided Progressive Tension Sutures

    Procedure: Progressive Tension Sutures

Interventions

  • ProcedureProgressive Tension Sutures

    In each patient, one side of the chest will receive progressive tension sutures inside the mastectomy pocket, from pectoral fascia to underside of mastectomy flap. 2-0 Vicryl about 15-20 sutures per chest. Both sides will receive bilateral drains (standard of care)

06

What researchers measure

Primary outcomes

  1. Total volume of Drain Fluid

    Participants will record drain outputs each time they empty drains in the Postoperative Drain Output Record (mL)

    Time frame: Visit 2, Day 7

  2. Total volume of Drain Fluid

    Participants will record drain outputs each time they empty drains in the Postoperative Drain Output Record (mL)

    Time frame: Visit 3, Day 14

  3. Total volume of Drain Fluid

    Participants will record drain outputs each time they empty drains in the Postoperative Drain Output Record (mL)

    Time frame: Visit 4, Day 30

07

Study locations

1 site
  • NYU Langone Health
    New York, New York 10016, United States
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Thomas.Calahan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Mar 26, 2021
StartActual
Mar 25, 2021
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Last update
Jan 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04818580
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Mar 25, 2021
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Last update
Jan 30, 2023

Study contacts

Alexes Hazen, MD FACS
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion